Abel Garcia-Pino (WELBIO – ULB) and his team uncovered the mechanism of toxicity used by the toxin-antitoxin systems (toxSAS) in bacteria.
2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
François Fuks (WELBIO – ULB) and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.
From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
Patrice Cani (WELBIO - UCLouvain) describes the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.
Pierre Close (WELBIO – ULiège) and Francesca Rapino describe how the regulation of transfer RNAs and modification of their anticodon impact the dynamics of protein synthesis and regulate protein folding and stability.
Decio Eizirik (WELBIO - ULB) et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.
Cédric Blanpain (WELBIO – ULB) and his team identify the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs
Director of the Laboratory of Stem Cells and Cancer (ULB), WELBIO investigator, Pr. Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.
Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Jean-François Collet's laboratory (WELBIO - UCLouvain) by funding a new joint research group at the Duve Institute.
These results from the team of Jean-Luc Balligand (WELBIO – UCLouvain) pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.